“UK is undergoing a burgeoning mental health crisis, which has created an urgent unmet need for the development of new treatments. Prescriptions for antidepressants more than doubled between 2006-2016 … and distressingly, suicide is now the leading cause of death among the young (with psychedelic usage linked to lower suicide risk).

Ketamine, a rapid acting anesthetic and established street drug sometimes called “Special K,” was approved by the FDA for treating depression last year.3 And now there are signs that psilocybin, the ingredient in so-called “magic” mushrooms and also classified as a Schedule I drug,4 may soon be used medically for depression.



Read more…